Dr Amy Chung completed her PhD at the University of Melbourne in 2011 and conducted a postdoc at the Ragon Institute of Massachussetts General Hospital (MGH), Massachussetts Institute of Technology (MIT) and Harvard. She returned to the University of Melbourne in 2015 and established her own laboratory in 2019. Her research focuses upon the application of cutting-edge experimental technologies to holistically examine functional antibodies against a range of infectious diseases including HIV, Mycobacterium Tuberculosis, Malaria and Influenza. This research can be used to design future antibody-based vaccines and can contribute to the generation of improved monoclonal antibody therapeutics.
Amy is an NHMRC Career Development (level 1) Fellow, American Foundation for AIDS Research (amfAR) Mathilde Krim Phase II Fellow and her laboratory is currently funded by NHMRC project grants. She has been awarded numerous prestigious awards including an Australian Postgraduate Award, American Australian Association Amgen Fellowship, NHMRC CJ Martin, MGH Medical Discovery Fellowship, Vaccine Journal and Edward Jenner Society Young Investigator and amfAR Mathilde Krim Phase I Fellowship. Amy has published a number of peer reviewed research articles in top tier journals including Cell, Science Translational Medicine, Nature Medicine, Nature Immunology and PNAS.